Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer

被引：7

作者：

Facchinetti, Francesco ^{[1
,2
,3
,4
]}

Caramella, Caroline ^{[5
]}

Auger, Nathalie ^{[6
]}

Planchard, David ^{[1
]}

Adam, Julien ^{[6
]}

Lacroix, Ludovic ^{[4
,6
]}

Remon, Jordi ^{[1
]}

Massard, Christophe ^{[7
]}

Soria, Jean-Charles ^{[3
,4
,6
]}

Friboulet, Luc ^{[3
,4
]}

Besse, Benjamin ^{[1
,4
]}

机构：

[1] Gustave Roussy Canc Campus, Dept Med Oncol, Villejuif, France

[2] Univ Hosp, Med Oncol Unit, Parma, Italy

[3] Gustave Roussy Canc Campus, INSERM, U981, 114 Rue Edouard Vaillant, F-94805 Villejuif, France

[4] Univ Paris Sud, Dept Med, Kremlin Bicetre Chatenay, France

[5] Gustave Roussy Canc Campus, Dept Radiol, Villejuif, France

[6] Gustave Roussy Canc Campus, Dept Med Biol & Pathol, Villejuif, France

[7] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France

来源：

TUMORI JOURNAL | 2016年 / 102卷

关键词：

ALK rearrangement; Crizotinib; Ceritinib; NSCLC; Primary resistance; INHIBITOR; CHEMOTHERAPY; PF-06463922; SAFETY;

D O I：

10.5301/tj.5000520

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report on the case of a patient affected by advanced non-small cell lung cancer (NSCLC) harboring an anaplastic lymphoma kinase (ALK) gene rearrangement who did not respond to crizotinib but subsequently benefited from treatment with ceritinib (LDK378). Although second-generation ALK inhibitors have shown activity in patients pretreated with crizotinib who experienced secondary resistance, this is the first report to date describing their efficacy in a case of primary resistance. Of note, none of the previously described molecular mechanisms explaining resistance to crizotinib was detected on either the initial or post-crizotinib biopsies. We hypothesize that crizotinib was powerless in controlling disease progression due to its inadequate inhibition of ALK signaling. Although we lack any molecular evidence elucidating the primary crizotinib resistance, we believe that ceritinib treatment led to tumor regression thanks to its superior biological potency.

引用

页码：S46 / S49

页数：4

共 10 条

[1]

Bauer TM, 2015, J THORAC ONCOL, V10, pS239

[2] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[3] MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients [J].

Cappuzzo, F. ;

Janne, P. A. ;

Skokan, M. ;

Finocchiaro, G. ;

Rossi, E. ;

Ligorio, C. ;

Zucali, P. A. ;

Terracciano, L. ;

Toschi, L. ;

Roncalli, M. ;

Destro, A. ;

Incarbone, M. ;

Alloisio, M. ;

Santoro, A. ;

Varella-Garcia, M. .

ANNALS OF ONCOLOGY, 2009, 20 (02) :298-304

[4] The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer [J].

Friboulet, Luc ;

Li, Nanxin ;

Katayama, Ryohei ;

Lee, Christian C. ;

Gainor, Justin F. ;

Crystal, Adam S. ;

Michellys, Pierre-Yves ;

Awad, Mark M. ;

Yanagitani, Noriko ;

Kim, Sungjoon ;

Pferdekamper, AnneMarie C. ;

Li, Jie ;

Kasibhatla, Shailaja ;

Sun, Frank ;

Sun, Xiuying ;

Hua, Su ;

McNamara, Peter ;

Mahmood, Sidra ;

Lockerman, Elizabeth L. ;

Fujita, Naoya ;

Nishio, Makoto ;

Harris, Jennifer L. ;

Shaw, Alice T. ;

Engelman, Jeffrey A. .

CANCER DISCOVERY, 2014, 4 (06) :662-673

[5] Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report [J].

Girard, Nicolas ;

Lou, Emil ;

Azzoli, Christopher G. ;

Reddy, Rekha ;

Robson, Mark ;

Harlan, Megan ;

Orlow, Irene ;

Yatabe, Yasushi ;

Nafa, Khedoudja ;

Ladanyi, Marc ;

Viale, Agnes ;

Kris, Mark G. ;

Riely, Gregory ;

Miller, Vincent ;

Klein, Robert J. ;

Matsuo, Keitaro ;

Pao, William .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :755-763

[6]

Lovly Christine M, 2015, Am Soc Clin Oncol Educ Book, pe165, DOI 10.14694/EdBook_AM.2015.35.e165

[7] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer [J].

Shaw, Alice T. ;

Kim, Dong-Wan ;

Nakagawa, Kazuhiko ;

Seto, Takashi ;

Crino, Lucio ;

Ahn, Myung-Ju ;

De Pas, Tommaso ;

Besse, Benjamin ;

Solomon, Benjamin J. ;

Blackhall, Fiona ;

Wu, Yi-Long ;

Thomas, Michael ;

O'Byrne, Kenneth J. ;

Moro-Sibilot, Denis ;

Camidge, D. Ross ;

Mok, Tony ;

Hirsh, Vera ;

Riely, Gregory J. ;

Iyer, Shrividya ;

Tassell, Vanessa ;

Polli, Anna ;

Wilner, Keith D. ;

Jaenne, Pasi A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) :2385-2394

[8]

Shen L, 2014, NEW ENGL J MED, V370, P2537, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]

[9]

Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]

[10] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models [J].

Zou, Helen Y. ;

Friboulet, Luc ;

Kodack, David P. ;

Engstrom, Lars D. ;

Li, Qiuhua ;

West, Melissa ;

Tang, Ruth W. ;

Wang, Hui ;

Tsaparikos, Konstantinos ;

Wang, Jinwei ;

Timofeevski, Sergei ;

Katayama, Ryohei ;

Dinh, Dac M. ;

Lam, Hieu ;

Lam, Justine L. ;

Yamazaki, Shinji ;

Hu, Wenyue ;

Patel, Bhushankumar ;

Bezwada, Divya ;

Frias, Rosa L. ;

Lifshits, Eugene ;

Mahmood, Sidra ;

Gainor, Justin F. ;

Affolter, Timothy ;

Lappin, Patrick B. ;

Gukasyan, Hovhannes ;

Lee, Nathan ;

Deng, Shibing ;

Jain, Rakesh K. ;

Johnson, Ted W. ;

Shaw, Alice T. ;

Fantin, Valeria R. ;

Smeal, Tod .

CANCER CELL, 2015, 28 (01) :70-81

← 1 →